お知らせ • Mar 29
Cell Source, Inc. announced delayed annual 10-K filing On 03/28/2025, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. お知らせ • Nov 21
Cell Source, Inc. Shared Positive Interim Results from Its Phase 1/2 First-In-Human Clinical Trial Conducted At the University of Texas Md Anderson Cancer Center Cell Source, Inc. shared positive interim results from its Phase 1/2 First-in-Human clinical trial conducted at The University of Texas MD Anderson Cancer Center. The trial has treated 15 patients using Cell Source's proprietary Veto Cell technology in stem cell transplants for malignant and non-malignant hematologic diseases. These early results indicate both safety and efficacy, marking a promising advance in stem cell transplant outcomes. Breakthrough Results for Safer and Effective Transplants Previously presented at the American Society for Hematology (ASH) Annual Meeting, the interim study results highlight: Consistent engraftment without severe GvHD: Achieved at 42 days post- transplant with T-cell-depleted, haploidentical stem cell transplants under reduced intensity conditioning (RIC).No toxicity linked to Veto Cells: No patients experienced adverse effects directly associated with Veto Cells. Enhanced protocol: A mild conditioning regimen, combined with Rituximab to prevent antibody-related complications, makes transplants safer and suitable for a broader range of patients. These findings underscore the potential of Veto Cells to increase access to life-saving allogeneic transplants for cancer patients and individuals with non-malignant blood disorders, supporting the strategic advancement of Cell Source's technology. Comparable Successes Demonstrate Market Potential The cell therapy and immunotherapy market has seen robust investor interest, with several start-up companies achieving multibillion-dollar valuations after clinical success. For example, Kite Pharma and Juno Therapeutics were acquired for $12 billion and $9 billion, respectively, following successful clinical outcomes and regulatory approvals in similar areas of cellular therapy. These precedents highlight the significant financial upside for novel treatments that achieve distinctive clinical efficacy and regulatory milestones. With Cell Source's Veto Cell platform showing early promise in achieving safer and thus more effective stem cell transplants without severe GvHD, the Company is strategically positioned to capitalize on this expanding market. The total addressable market (TAM) for hematological therapeutics, including both cancer and nonmalignant diseases, is estimated to be in excess of $100 billion, underscoring the vast commercial potential for Veto Cells to gain market traction as the platform advances through clinical trials. Pathway to Market and Competitive EdgeCell Source's Veto Cell technology offers a unique advantage by combining reduced immune suppression with avoidance to GvHD, making it an attractive alternative to current stem cell transplant methods. The Company's Veto Cell platform is also being developed for organ transplant applications, potentially allowing for partially mismatched donors as well as reducing or possibly even eliminating reliance on lifelong immunosuppression post-transplant. お知らせ • Aug 15
Cell Source, Inc. announced delayed 10-Q filing On 08/14/2024, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Apr 02
Cell Source, Inc. announced delayed annual 10-K filing On 04/01/2024, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. お知らせ • Aug 17
Cell Source, Inc. announced delayed 10-Q filing On 08/15/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. New Risk • Jun 12
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.9m free cash flow). Shares are highly illiquid. Negative equity (-US$12m). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$14.9k market cap). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Shareholders have been diluted in the past year (8.0% increase in shares outstanding). お知らせ • May 17
Cell Source, Inc. announced delayed 10-Q filing On 05/16/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Jul 22
Cell Source, Inc. Announces Board Resignations Cell Source, Inc. announced that onJuly 18, 2022, each of Ben Friedman and David Zolty resigned his position as a director of the company. お知らせ • May 13
Cell Source, Inc. announced delayed 10-Q filing On 05/12/2022, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Apr 01
Cell Source, Inc. announced delayed annual 10-K filing On 03/31/2022, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. お知らせ • Mar 21
USPTO Issues New Patents for Cell Source's Veto Cell Technology Cell Source, Inc. announced that it has received USPTO issuance notices for two patents covering its Veto Cell technology. The first patent, "Veto Cells Generated from Memory T Cells", describes Veto Cells that safely elicit patient acceptance of transplanted cells, such as stem cells, by overcoming the barriers of graft rejection and graft versus host disease (GvHD). Veto Cells are also capable of fighting potential viral and bacterial infections and can treat unresponsive cancers or cancers where limited treatment options exist. The second patent, "Methods of Transplantation and Disease Treatment", describes an invention in which Veto Cells act as unique, powerful companion cells that allow cellular therapies such as CAR-T and NK to be safely tolerated by the patient without transplant rejection or graft vs. host disease (GvHD) – while increasing overall combined treatment impact. The patents describe Veto Cell inventions in which Veto Cells work in conjunction with existing stem cell transplant therapies to protect the patient from transplant-related complications while increasing overall treatment efficacy, as well as inventions in which Veto Cells have been exposed to third-party antigens, thereby enabling Veto Cells to work on their own to effectively target cancers that have not responded to genetically modified T-cell therapies or where these therapies do not currently exist. お知らせ • Mar 14
Cell Source, Inc. Announces its Veto T-Cell Bone Marrow Transplant Safely Demonstrates Potential Cure for Sickle Cell Anemia in Preclinical Trials Cell Source, Inc. announced that its fully mismatched mouse Veto Cell based BMT protocol has overcome significant challenges to durably prevent the onset of the pathological parameters of sickle cell disease (SCD) including complete conversion to normal, donor-derived red blood cells. The study, correction of murine sickle cell disease by allogeneic hæmatopoietic cell transplantation with anti-3rd party veto cells, published online by BMT Journalon March 3, 2021. As noted in BMT Journal, the Veto Cell protocol was able to safely and efficaciously achieve durable, donor-derived chimerism in mice prone to sickle cell disease (i.e., the donor's transplanted healthy cells begin to be produced by the recipient mice instead of the host defective cells) and prevent onset of SCD pathology by overcoming several significant challenges, including: the need for safer partially or fully mismatched bone marrow transplantation (BMT) protocols; the challenge of transplant rejection under reduced intensity conditioning (RIC); and the possibility of graft vs. host disease under RIC. A phase 1/2 clinical trial is currently in progress testing the safety and efficacy of the company’s Veto Cells in patients with hematological cancers or with non-malignant hematological diseases including SCD. お知らせ • Feb 26
Cell Source, Inc. Appoints Joseph Rosenthal to Scientific Advisory Board Cell Source, Inc. announced that Joseph Rosenthal has joined its Scientific Advisory Board. Dr. Rosenthal is currently the Director of Pediatric Hematology-Oncology and Barron Hilton Professor & Chair in Pediatrics at City of Hope National Medical Center in Duarte, CA.